余仙

Cooley advised Fangdd on its $78 million initial public offering of 6,000,000 American depositary shares, each representing 25 class A ordinary shares. The underwriters have a 30-day option to purchase up to 900,000 additional shares. The transaction represents Cooley’s first completed IPO out of its newly launched Hong Kong office. Partner Will Cai led the Cooley team advising Fangdd. Founded in 2011 by former real estate agents Yi Duan and Xi Zeng, Fangdd now trades its securities on the Nasdaq Global Select Market under the symbol “DUO.”

Cooley advised Legend Biotech on its $487.3 million initial public offering of 21,188,750 American Depository Shares (ADSs). Legend Biotech, whose securities now trade on the Nasdaq Global Select Market under the symbol “LEGN”, is global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Partners Div Gupta, Rob Phillips, Will Cai, Michael Yu and Rich Segal led the Cooley team.

Cooley advised biotechnology company Keymed Biosciences on its HK$3.1 billion (US$400 million) initial public offering on the Hong Kong Stock Exchange. Partners Yiming Liu, Michael Yu and Will Cai led the Cooley team advising Keymed Biosciences on its public debut, which also included Yiying Wang, Xiaoyu Xu, Kaiting Yang, Henry Wang, Bridget Wang and Iris Yang.

Cooley advised the underwriters on Smart Share Global’s $150 million initial public offering of 17,650,000 American Depositary Shares. Goldman Sachs, Citigroup Global Markets  and China Renaissance Securities (Hong Kong) Limited acted as joint bookrunners and for the offering. Smart Share Global, whose securities now trade on the Nasdaq Global Select Market under the symbol EM, is a consumer tech company providing mobile device charging service. Partners Will Cai, Michael Yu and David Peinsipp led the Cooley team.

Cooley advised Asymchem Laboratories, a contract development manufacturing organization (CDMO) serving the global pharmaceutical industry, on its HK$7.15 billion (US$916 million) initial public offering – marking the largest healthcare IPO in Hong Kong this year – of 18,415,400 H shares, which now trade on the Hong Kong Stock Exchange. Partners Yiming Liu and Michael Yu led the Cooley team advising Asymchem.